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In this thesis the vaccine types, adverse events and the development of vaccines were dis-
cussed.  
 
Traditional vaccine types manufactured are live-attenuated, inactivated, subunit and toxoid 
vaccines. Also, combinations of these vaccine types are common. New vaccines that are 
manufactured include DNA technology. There are DNA vaccines and recombinant protein 
subunit vaccines. 
 
Adverse events are the possible side effects that immunization can cause. They do hap-
pen in a certain frequency and can range from mild reaction to severe. Adverse events are 
monitored from the beginning of the development of vaccines. 
 
Development of a vaccine is challenging and difficult. It includes many phases, high costs 
and can take several years, with no guarantee of success. Development starts with finding 
the suitable antibodies and antigens that provide the immunity against wanted disease. 
Then a prototype of vaccine is made and tested with animals. If the tests are showing good 
results, the vaccine is going to clinical trial phases, where it is tested with humans. If every-
thing goes well, it is possible to apply marketing license. When the vaccine is in the mar-
ket, it is still under surveillance for the adverse events.  
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Tässä opinnäytetyössä käsitellään rokote tyyppejä, haittavaikutuksia ja rokotteiden kehittä-
mistä. 
 
Perinteiset rokotetyypit, joita valmistetaan, ovat elävät heikennetyt, inaktivoidut, subunit ja 
toksoidi rokotteet. Näiden rokote tyyppien kombinaatiot ovat myös yleisiä. Uusien rokottei-
den valmistuksessa käytetään DNA teknologiaa. On olemassa DNA- ja rekombinantti pro-
teiini subunit rokotteita.  
 
Haittavaikutukset ovat mahdollisia sivuvaikutuksia, joita immunisaatio voi aiheuttaa. Näitä 
tapahtuu tietyllä frekvenssillä ja ne voivat vaihdella miedoista reaktioista vaarallisiin. Haitta-
vaikutuksia seurataan rokotteiden kehittämisen alkamisesta asti.  
 
Rokotteen kehittäminen on haastavaa ja vaikeaa. Se sisältää monia vaiheita, se on kallista 
ja voi viedä useita vuosia, ilman mitään varmuutta onnistumisesta. Kehittäminen alkaa so-
pivien vasta-aineiden ja antigeenien löytämisestä, jotka tarjoavat immuniteetin haluttua 
tautia vastaan. Sen jälkeen valmistetaan rokotteelle prototyyppi ja sitä testataan eläimillä. 
Jos testit näyttävät hyviä tuloksia, voi rokote edetä kliinisiin kokeisiin, missä sitä testataan 
ihmisillä. Jos kaikki menee hyvin, on mahdollista hakea markkinointi lupaa. Kun rokote on 
markkinoilla, sen mahdollisia haittavaikutuksia seurataan vielä. 
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 Introduction 
World Health Organization (WHO) defines a vaccine as follows: 
A vaccine is a biological preparation that improves immunity to a particular            
disease. A vaccine typically contains an agent that resembles a disease-causing 
microorganism, and is often made from weakened or killed forms of the microbe, 
its toxins or one of its surface proteins. The agent stimulates the body's immune 
system to recognize the agent as foreign, destroy it, and "remember" it, so that the 
immune system can more easily recognize and destroy any of these microorgan-
isms that it later encounters. [WHO, 2018.] 
Vaccines are proteins, polysaccharides, or pathogenic nucleic acids, that are used to 
stimulate immunity, to eliminate or weaken pathogens or pathogenic products. In other 
words, vaccines are biological preparations that help to acquire immunity against dis-
eases. Vaccines are usually virus or bacterium-based preparations, that fight against 
diseases, caused by viruses or bacteria. There are different kind of vaccines researched 
and developed. Pediatric vaccines are the most researched kind. There is also influenza, 
adult, cancer, therapeutic, hepatitis and other vaccines.  
The aim of this thesis is to discuss vaccines; how they function, how the production pro-
cesses are developed, manufacturing of vaccines and what the future looks like. The 
production process is similar to the manufacturing of other biopharmaceutical              
preparations because the use of bacteria, viruses and even genome. Researchers con-
tinue to fight against diseases, infections and the variant strains of influenza. 
Vaccines have had a huge impact in the world, especially in low-income countries, where 
there are lots of people in small areas and poor hygiene. Different organizations try to 
help these countries by offering vaccination programmes. Vaccination can reduce 
health-care costs for many countries, give longer life expectancy and lower mortality, 
which then again helps the economy. Vaccines can even effect in the injustice between 
rich and poor, by being available for both. Travelling is also safer, when it is possible to 
be protected against different diseases. [Andre et al., 2007.] 
For the last half century, vaccines have eliminated contagious diseases and prevented 
millions of deaths and potential disabilities. Even so, vaccinating is not always ethically 
unproblematic. Vaccines are given to healthy people and small children that cannot make 
the decision on their own to be vaccinated. Ethics of vaccination is around three medical 
2 
 
 
principle: beneficence, autonomy and justice. Everyone in the vaccination programme 
must follow these principles according to their role and decisions. [Hedman et al., 2011: 
776.]  
 Vaccines and How They Work 
In this chapter, the vaccine mechanisms are discussed through immunization and im-
munity. Explanations are also given for antibodies and antigens. The traditional vaccine 
types are introduced in section 2.2. 
2.1 Mechanisms of Vaccines 
To understand how vaccines function, one needs to have knowledge about antibodies, 
antigens and immunization. Antibody is a protein that immune system has created in the 
presence of specific antigen (ANTIbody GENeration). Antibodies help to counter the ef-
fects of antigens, by attaching to them. Antigens are substances that stimulates the im-
mune system to create antibodies. [Glossary of Terms, 2018.] 
Immunization means making the body resistance against germs (germ = pathogenic mi-
croorganism). This happens with the help of antigens that stimulates the antibody pro-
duction and cell-mediated immunity. When the immunity has been acquired, the body is 
resistant against specific antigens. [Hedman et al., 2011:770.] 
Active and passive immunity are part of adaptive immune system. If the immunity is 
based on body's own cell activity (antibodies are made in the body), it is called active 
immunity. Active immunity can be achieved by natural infection or artificially with vac-
cination. Resistance is acquired with passive immunization, if antibodies are created 
somewhere else. Passive immunity happens naturally through maternal antibodies or 
through artificially made monoclonal antibodies. Active immunizations, in other words, 
vaccinations biggest advantage is that once acquired protection can last years. Protec-
tion trough passive immunization usually lasts only few months. [Hedman et al., 
2011:770.] Sometimes adjuvants are needed to help enhance the immunity. 
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Immunity can be humoral or cell-mediated and these are often working together. [Hed-
man et al., 2011:770]. Humoral immunity is mediated by B-lymphocytes, when cell-me-
diated immunity by T-lymphocytes (lymphocyte = type of white blood cell). B-lympho-
cytes can divide to memory cells and cells that form antibodies. T-lymphocytes can rec-
ognize and destroy cells infected by a virus and help B-lymphocytes to create specific 
antibodies. Both lymphocytes can detect antigens. [Cruse & Lewis, 2009: 69, 432, 682, 
686, 706.] 
The function of vaccines is built on immunity. Immunity system is a collection of organs, 
cells, and molecules inside the body that identify germs as foreign invaders and reacts 
by producing proteins called antibodies. Antibodies destroy the germs and memorizes 
the invaders. They remain in the bloodstream and can detect if the same germs enter 
the body again to infect it. Since antibodies have already once destroyed them earlier, 
they can annihilate them before infecting the body. [How Vaccines Work, 2016.]  
Vaccines work the same way, but without the body getting ill. They are made of patho-
gens disease causing properties that are weakened or killed first, by biological, chemical 
or physical means, while retaining its ability to induce an effective immune response [Ho 
& Gibaldi, 2003:315.] Immunity system reacts to the weakened or killed germs, the same 
way they do, when being invaded by the disease. New antibodies are made and germs 
have been memorized.  [How Vaccines Work, 2016.]  
2.2 Main Types of Vaccines 
 Vaccines improve immunity against a specific disease. Vaccination is one of the most 
effective ways to prevent infectious diseases from spreading. [Route of Administration, 
2018.] Vaccine can be given orally or as an injection to a muscle, under the skin, inside 
the skin, or as a nasal spray (e.g. influenza vaccine). Vaccines that are given under the 
skin are usually injected in the shoulder. The ones that are given to the muscle are given 
to the thigh or to the shoulder muscle. Vaccine is absorbed better from muscle than from 
fatty tissue. [Hedman et al. 2011: 835-6.] 
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Each vaccine type is designed to instruct antibodies to destroy certain germs. The main 
four vaccine types that scientist create are live-attenuated, inactivated, subunit and tox-
oid vaccines. These are categorized by the antigen that is used in their manufacturing. 
Formulation of these vaccine types affects their use, storing and how they are controlled. 
[Types of Vaccine, 2018.] 
 
Besides the traditional vaccines, there are also combination vaccines. They are defined 
as immunizing preparations which have antigens from several pathogenic microorgan-
isms. This type of vaccine can create immunity against more than one disease. For ex-
ample, MMR is a typical combination vaccine, which has live-attenuated viruses from 
measles, mumps and rubella. MMR vaccine protects against these diseases and is a 
part of childhood vaccination programme. [Cruse & Lewis, 2009:185.] 
2.2.1 Live-attenuated vaccines 
Live-attenuated vaccines resemble the natural infection, but in the weakened form. It is 
made of attenuated form of the germ that causes a disease, but retains the ability to 
infect and replicate in the vaccinated host. The weakened form is achieved by passaging 
the pathogen into tissue cultures repeatedly. The weakest variants of the pathogen are 
then selected from each repetition. [Ho & Gibaldi, 2003:315.] Live-attenuated vaccine 
can give a lifetime protection against germs that are responsible for the disease, only 
from one or two doses to the body. These vaccines can be used against for example 
measles, smallpox and yellow fever, which are caused by a virus. Tuberculosis vaccine 
is a bacterium based live-attenuated vaccine. Unfortunately, this vaccine type has some 
restrictions. It needs to be kept in cool, so delivery and storing might be an issue. Also, 
people with weakened immune systems might not be able to receive this type of vaccine 
because it contains a small amount of the attenuated live virus. [Vaccine Types, 2017.] 
Some viruses cannot be attenuated enough to be given to humans without a risk of get-
ting the disease, for example HIV virus (Human Immunodeficiency Virus). 
2.2.2 Inactivated vaccines 
In the inactivated vaccines the pathogen is inactivated by chemical or physical means or 
combination of both. Unfortunately, inactivation process could destroy the antigen con-
formation required to elicit protective immunity. [Ho & Gibaldi, 2003:316-317.] Inactivated 
vaccines differ from live-attenuated vaccines by using the killed version of the germ that 
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causes illness. It is not as effective as live-attenuated vaccine and does not provide pro-
tection of a lifetime, but because it uses the killed version of the germ, it can be received 
by the people who have weakened immunity systems. It needs to be taken periodically 
over time to get permanent immunity. This type of vaccine can protect against for exam-
ple hepatitis A and rabies, which are caused by a virus. Typhoid vaccine is a bacterium 
based inactivated vaccine. [Vaccine Types, 2017.] 
2.2.3 Subunit vaccines 
Subunit vaccine is a type of vaccine that uses only the protein part of the germ and does 
not contain its genetic material. To prepare subunit vaccines, one must have identified 
the key antigenic target to include in the vaccine. Immunogens of these vaccines are 
composed of bacterial proteins, polysaccharides or conjugates of both. [Ho & Gibaldi, 
2003:318-319.] This type of vaccine gives a strong immune response because it targets 
the key parts of the germ. There are similarities with inactivated vaccines. Subunit vac-
cine can also be given to infants and people with weakened immunity system. It needs 
to be taken several times over period to keep the protection against diseases. [Vaccine 
Types, 2017.] This type of vaccine is used to protect against hepatitis B and pneumo-
coccal disease [Types of Vaccine, 2018]. 
2.2.4 Toxoid vaccines 
Toxoid is a chemically inactivated toxin. Toxoid vaccines are little different from the vac-
cines discussed previously. They use the germs toxin that causes a disease. The im-
munity is created to the parts that causes the disease, so instead of targeting the whole 
germ, the immune response targets only the toxin. A toxoid vaccine does not give a 
lifetime protection, thus booster shots might be needed. This type of vaccine protects 
against diphtheria and tetanus. These diseases are caused by a bacterium. [Vaccine 
Types, 2017.] 
 
Benefits of using a vaccine that contain live organisms is that they are natural and easy 
to store to refrigerators and coolers. They also often provide a lifetime protection against 
diseases. Problems that occur with vaccines that contains live organisms are that they 
are hard to produce, they might spread to the environment or change to pathogenic. 
Preservation might become problem with very warm countries because these vaccines 
need to be kept cool, usually between +2 ̊C to +8 C̊. Some vaccines need to be stored 
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below zero degrees, -25 C̊ is the minimum. Other vaccines, like inactivated or toxoid 
vaccines, have benefits of easy use, they cannot induce an infection and they have only 
little adverse events. Problems of these are that they are much weaker than the ones 
that use live organisms, so they provide a weaker immunity or one that lasts less than a 
lifetime. Sometimes the antibodies will not protect as they are meant to and they can be 
harmful. [Hedman et al. 2011: 773.] 
 History of Vaccines 
The use of vaccination to immunize people against infectious diseases has influenced 
the world for the past 200 years. It is one of the most remarkable achievements in the 
history of medicine. Early form of vaccination was developed in 1100's China. This 
method is called variolation, and it arrived at Europe around 1700's. Variolation is dis-
cussed more specifically in section 3.1.  
Most vaccines invented before 20th century, were often created by accident. Scientists 
tested different techniques and substances very freely because there were not much 
restrictions or regulations concerning it. Most of the experiments failed and possibly 
caused injuries, disabilities or let to the death of the test subjects, but sometimes the 
experiments succeeded. After the realization that diseases were caused by microorgan-
isms, the first created vaccines were usually bacterium based because viruses were too 
small to be detected with microscopes of that time. 
3.1 Variolation 
Smallpox is a disease caused by a variola virus. Smallpox cause vesicular and pustular 
skin injuries that are painful. Risk of death was very high before the vaccine was in-
vented. [Cruse & Lewis, 2009.] 
Variolation was the early form of vaccination. It was based on inoculating the smallpox 
virus in to person’s skin to produce immunity against the disease. A lancet or a needle 
was used to put pulverized dried smallpox scabs or pustule fluid into the slightly cut skin 
of the person. Drying made the form of the virus milder, which was shown as a lower 
fatality rate. Variolation was developed in China as early as 1100’s. It came in Europe 
600 years later. Nowadays it is not used anymore as a medical practice. It was not that 
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safe because variolated persons could still transmit smallpox to others and the inocula-
tion method spread diseases, for example syphilis and hepatitis. [Louten J., 2016.] 
3.2 Remarkable moments 
Edward Jenner, born in 1744, is often referred to as the founder of immunology, based 
on his contribution of the first reliable method of giving lasting immunity to a major con-
tagious disease [Cruse & Lewis, 2009:424]. He figured out that the inoculation of cowpox 
could create immunity against smallpox. This procedure was called vaccination and it 
came from the word "vacca", which means cow in Latin. First smallpox vaccine was de-
veloped in 1798. This discovery lead to eradication of smallpox in 1979. [All Timelines 
Overview, 2018.] 
Louis Pasteur followed in Edward Jenner’s footsteps and successfully created the first 
live-attenuated cholera vaccine in 1879. Few years later he also created vaccine against 
rabies. Development of bacteriology led to new discoveries in bacterial vaccine develop-
ment, for example the creation of plague vaccine in the 1897. [All Timelines Overview, 
2018.] In the late 19th century Robert Koch proved that infectious diseases are caused 
by microorganisms and that each one of them are responsible for a particular disease. 
Now there are four categories recognized as disease causing microorganisms or patho-
gens: viruses, bacteria, fungi and parasites. [Murphy Etc. 2008:1.] This information made 
a major impact in the research of vaccines. 
Alexander Glenny created a method to inactivate tetanus toxin with formaldehyde in the 
1923. This method was applied to create other vaccines. Between the 1950 and 1985 
viral tissue culture methods developed, for example growing viruses in the laboratories. 
It meant prompt discoveries and innovations, which lead to polio vaccine in the 1955. 
Since then, polio has been 99% eliminated from the world. [All Timelines Overview, 
2018.] 
Researchers concentrated in the mid-20th century to the creation of vaccines for the 
childhood diseases, such as measles and rubella. Childhood diseases were especially 
targeted because children have much weaker immune systems compared to adults. Af-
ter the founding of the United Nations International Children's Emergency Fund 
(UNICEF) in the 1946 and the World Health Organization (WHO) in the 1948, children's 
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immunization programmes were introduced to the world. [Stern & Markel, June 2005.] In 
1974 WHO launched Expanded Programme on Immunization (EPI), which targeted diph-
theria, whooping cough, tetanus, measles, poliomyelitis and tuberculosis. The goal was 
to establish immunization for all children by 1990. [The Expanded Programme on Im-
munization, 2018.] 
Figure 1 describes a few remarkable moments in the history of vaccines. It starts as early 
as 12th century China, in the form of variolation. The important evolving steps of vaccina-
tion are focused on the late 18th to 20th centuries.  
Figure 1. Brief timeline of vaccine history [All Timelines Overview, 2018]. 
3.3 Eradication and Elimination of Diseases 
This section is divided to two categories and it is about eradication and elimination of 
diseases. Eradication is discussed in section 3.3.1 and elimination in section 3.3.2. 
3.3.1 Eradication 
When talking about vaccines, eradication means that the disease is destroyed with the 
cause of the disease.  Elimination then again means that the disease is eliminated but 
the disease-causing factors are remaining. Eradication is the main target for an immun-
ization programme, but only smallpox has been eradicated completely (1979) from eve-
rywhere. After that the second-best goal is to eliminate diseases from different parts of 
the world, and hope that it would eventually lead to the eradication from the whole world. 
Polio is hopefully the next disease to be eradicated. At the moment, type 2 poliovirus has 
been eliminated globally, but types 1 and 3 are still met in some countries. Eradication 
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of a disease is possible with an effective vaccine, but it also needs majority of people in 
the world, to have immunity in all regions, for constant period of time and a good             
surveillance. [Andre etc., 27.11.2007.] Eradication can be confirmed after there has not 
been any reported disease cases in a couple of years. 
3.3.2 Elimination 
Elimination of disease can be done locally, without the need to destroy the causative 
microorganism, globally. Measles has been eliminated in most of the developed coun-
tries and completely from the United States of America. This has been achieved through 
a two-dose vaccination programme. Combination vaccine of measles, mumps and ru-
bella has high hopes of eliminating, and someday eradicating, rubella and mumps. Un-
fortunately, even though some disease might have been eliminated locally, it does not 
mean that the danger of infection is over because the disease-causing factor has not 
been destroyed. It can only need one person who carries the pathogen, to visit disease 
eliminated country, to reintroduce the disease all over again. [Andre etc., 27.11.2007.] 
Proof that eliminating measles, mumps and rubella is possible in the future is that it has 
already happened in Finland. Figure 2 shows how vaccination programme effected in 
Finland and eliminated these diseases. Elimination happened through a two-dose vac-
cination programme that begun in the 1982. As can be seen from the Figure 2, the cases 
of these diseases have started to decrease clearly from 1982. The rate has been down-
ward since 1990. Measles cases have had the most significant difference between the 
years 1960 to 1994. Cases have dropped from about 80 000 cases in a year, to about 
10 cases in a year. [Peltola et al., 1994.] Measles was completely eliminated from Finland 
in 1996. Since then it has not been met in Finland. [Heinonen et al., 1998]. 
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Figure 2. Cases of measles, mumps and rubella in Finland from 1960 to 1994 [Peltola et al., 
1994].  
Even though eradication and elimination of diseases has happened after vaccines were 
introduced to the world, some studies argue that vaccines did not have actually that huge 
impact on the eradication or elimination. It might have made the elimination just happen 
faster. These studies are based on the thought that availability of clean water, improve-
ment of hygiene, sanitation and development of modern health made the impact for elim-
ination of diseases. Figure 3 shows that the polio, smallpox and diphtheria cases had 
been reduced already, even before the vaccines were introduced. Typhoid fever disap-
peared with no vaccination programme.  
 
Figure 3. Vaccines effect on diseases [Borne, 2005]. 
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 Side Effects of Vaccination 
Adverse events are reactions that are undesired. They could be referred as a side ef-
fects. Vaccines have lots of components and each component can add risk. It must be 
assured that vaccine components do not cause any danger to vaccine safety, used sep-
arately and in a combination. Some vaccines can have components to strengthen im-
mune response with adjuvants and conjugated proteins. They can also include compo-
nents to lessen contamination during the production process. The used components can 
be antibiotics and/or stabilizers. [Adverse Events: Causes, 2018.] 
Adverse Event Following Immunization (AEFI) can be any adverse medical hazard, 
which happens after immunization, but does not necessarily happen because of the vac-
cine. These events can be compartmentalized to five categories by the cause of the 
event. These events can be related to vaccine products, vaccine quality defects, immun-
ization errors, immunization anxiety or coincidental events, which are discussed in sec-
tions 4.1 - 4.5. 
4.1 Vaccine Product-Related Reaction 
Vaccine product-related reaction is the first category of the AEFI's. This reaction is 
caused by one or more of the vaccine components. In this case, the contents of the 
vaccine are causing the side effects. Swelling of limbs, after vaccination, is one example 
of this reaction. [Adverse Events: Classification, 2018.] 
4.2 Vaccine Quality Defect-Related Reaction 
Second category is vaccine quality defect-related reaction. It is caused by vaccine quality 
defects. These defects could occur, for example, if polio virus has not been completely 
inactivated in the vaccine. In this case, the quality defect could lead to paralytic polio, 
which paralyses the spinal cord. [Adverse Events: Classification, 2018.] 
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4.3 Immunization Error-Related Reaction 
Third category is immunization error-related reaction. This error could be caused by the 
improper handling of vaccine, mistakes in the description or in the administration. This 
could happen, for example, because of contaminated vial. [Adverse Events: Classifica-
tion, 2018.] 
4.4 Immunization Anxiety-Related Reaction 
Fourth category is immunization anxiety-related reaction, which arises from the anxiety 
concerning the immunization [Adverse Events: Classification, 2018]. This anxiety could 
be caused by the lack of knowledge in the vaccine or because of the reportage of the 
side effects that people have had from the vaccine. The more people hear news about 
the side effects that the vaccine might have caused, the more they start to question its 
safety. 
4.5 Coincidental Event 
Fifth category is called coincidental event, which is caused by something else than the 
error or anxiety of the immunization or the vaccine [Adverse Events: Classification, 
2018]. For example, nausea occurs at the same time as the vaccine is given, but it is 
caused by something else, like food poisoning.  
Ideal situation would be that vaccines would not cause adverse events and would com-
pletely prevent the infection they target, but unfortunately, it is impossible with the current 
technology. Currently, the only way is to minimize adverse events and make sure that 
the vaccines are used safely. Adverse events of vaccines occur with a certain frequency. 
Common and usually minor reactions can be fever and malaise. Rare and more severe 
reactions can be allergic reactions to vaccine antigen or its component. Frequency differs 
from very rare (<0, 01%) to very common (≥ 10%). [Adverse Events: Frequency and 
Severity, 2018.] 
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4.6 AEFI surveillance system 
It is important to survey adverse events because vaccines are meant to prevent diseases 
and are given to healthy people. The tolerance for risks is lower compared to drugs that 
are made for curing people. That is why there is a major need to detect and investigate 
any adverse event following immunization. Surveilling adverse events helps the vaccina-
tion programmes to become successful. 
AEFI surveillance system is meant to help the National Regulatory Authority (NRA) by 
observing and reporting the adverse events. NRA is the agency which makes sure that 
vaccines are safe, efficient and their quality hits the standards. Safety of the vaccines is 
mostly measured by the adverse events. AEFI surveillance system oversees that. For a 
strong AEFI surveillance system, it is important that the communication between NRA 
and National Immunization Programme (NIP) is good, to ensure the use of worldwide 
data. [Interactions Between AEFI and ADR Surveillance Systems, 2018.] 
AEFI surveillance system has many objectives like detecting, correcting and preventing 
immunization errors, caused by mistakes in preparation, handling, preserving, or in ad-
ministration. It is crucial to identify vaccine reaction problems and prevent false blames 
on adverse events, when there is unrelated cause to the immunization. AEFI surveillance 
system is also reducing the incidence of injection reaction by educating the public. These 
reactions can be caused by anxiety about the vaccine or the fear of pain of the injection. 
Teaching about the vaccines, their risks and responding to concerns, helps to maintain 
the public’s confidence. One important task that AEFI surveillance system has, is the 
estimation AEFI’s in the population, for a new vaccine, by comparing the trial and the 
international data about adverse events.  [AEFI Surveillance Components, 2018.] 
4.7 Evolution of an Immunization Programme 
Immunization programme is a programme that targets to give health benefit, by providing 
immunization against diseases. The aim is to eradicate them. Many of the programmes 
are targeting vaccination of children, to ensure that they will also benefit from the life-
saving inventions. One good example of an immunization programme is EPI that was 
established in the 1974 by the 27th World Health Assembly. It recommended that all chil-
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dren from all countries should receive a protection against tuberculosis, tetanus, diph-
theria, measles, whooping cough and poliomyelitis. [National Programmes and Systems, 
2018] Because the immunization programmes have been beneficial and many of the 
ones feared diseases are only rarely seen nowadays, the concentration of people has 
moved to the adverse events, instead of the severity of the diseases. However, there is 
a problem how to prove the causal relation between the vaccine and the adverse event. 
[Hedman etc. 2011: 841.] 
Figure 4 shows potential stages in the evolution of an immunization programme.        
Stage 1 is the phase, where there are lots of cases of a disease and the vaccine has not 
been introduced yet to the market. Stage 2 is after effective vaccine has been introduced 
to prevent a disease. Disease rate will decrease, but number of adverse events will fol-
low. The threat of the disease vanishes and attention moves to adverse events. Stage 3 
is the loss of confidence in the vaccine. When more adverse events are introduced, peo-
ple will start to question the safety of the vaccine and vaccination rate decreases. With 
less vaccination, the outbreak of the disease occurs. The loss of confidence is always a 
problem for the succession of the vaccination programme. Stage 4 is resumption of con-
fidence. Confidence is gained through the outbreak of the disease or by an alternative 
vaccine for the disease. Vaccination levels increase again and disease cases decrease. 
Stage 5 is the eradication of the disease (if the disease is vaccine-preventable), for ex-
ample smallpox was eradicated. Vaccination is stopped when eradication is confirmed 
and adverse events do not happen.  [Vaccine Safety in Immunization Programmes, 
2018.]  
 
Figure 4. Potential Stages in the Evolution of an Immunization Programme [Vaccine Safety in 
Immunization Programmes, 2018]. 
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4.7.1 Pandemrix vaccine in Finland 
One example of adverse event is the swine flu pandemic in Finland 2009. Vaccine 
against the swine flu was called Pandemrix. It was questioned to cause increase in nar-
colepsy cases in kids and young people. [THL 2018, Narkolepsia ja sikainfluenssaro-
kote.] Narcolepsy is a sleep disorder, which appears as excessive sleepiness, sleep pa-
ralysis, hallucinations and sometimes as episodes of cataplexy [National Sleep Founda-
tion, 2018].  
 
The Pandemrix vaccine was taken away from use, as a precaution. Pandemrix vaccine 
and the model vaccine before it had gone through examinations, demanded by EU’s 
medical legislation and had gotten the license to sell. In the examination, it did not occur, 
that there might be side effects relating to narcolepsy. [THL 2018, Narkolepsia ja si-
kainfluenssarokote.] Since the vaccine was new and created in a short period of time, 
there was not any recordings of the long-term side effects. 
 
THL (The National Institute for Health and Welfare) started research connections be-
tween narcolepsy, swine flu and Pandemrix vaccine in 2010. In the final report of this 
research, THL admitted that Pandemrix vaccine had influenced in the increase of the 
narcolepsy cases in people between ages 4 to 19. Most likely, the vaccine had increased 
narcolepsy synergy between inheritances and other environment factors. [THL 2018, 
Narkolepsia ja sikainfluenssarokote.] 
 
In May 2013 THL published a new report, where they stated that according to surveil-
lance information of the Pandemrix vaccine, it can be said that the vaccine increased the 
possibility to have narcolepsy in people under 65 years old, who had had the vaccine 
compared to people, whom were unvaccinated. In the year 2015, THL stated that the 
rate of new narcolepsy diagnoses had returned to the same level as it was before the 
Pandemrix vaccine. [THL 2018, Narkolepsia ja sikainfluenssarokote.] 
 Development and Manufacturing of Vaccines 
Vaccines are made the same way as other biological preparations, but with even more 
higher standards, to ensure that the final product is as pure as possible. Every step from 
the beginning must be validated and the whole process must happen in controlled and 
safe environment. Vaccines must be safe from contaminants, otherwise rate of adverse 
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events will rise. Safety of the new vaccine is tested in the clinical trials. Vaccine devel-
opment has a lot of challenges, and besides finding safe and effective adjuvants, anti-
gens and delivery systems, it is important to be in balance with cost, risks and benefits 
[Nascimento & Leite, 2012.] 
Validation is a crucial part when manufacturing a biological preparation. It is often said 
that what is not validated, is not done. Validation is a regulation requirement and gives 
assurance of quality, provides economic value and helps to understand and control the 
process. Possible mistakes are easy to find when every step is validated. It also works 
as a proof that everything has been done according to regulations. [Lane, 2016.] 
Vaccines are prepared following Good Manufacturing Practices (GMP). A cleanroom is 
a part of GMP regulation for vaccine development. It is a room where the environment is 
controlled. Humidity, air and temperature are controlled alongside with the number of 
people entering the room at the same time. Contaminants in the air are controlled by 
High Efficiency Particulate Air (HEPA) filters. Humans are the biggest source of contam-
ination. Cleanrooms are categorized by permissible number of particles inside a volume 
of one cubic meter (m3) of air. There are three different standards for this: ISO, EU and 
US-FDA. Cleanroom standards in the vaccine manufacturing depends on the vaccine 
type. Different parts of manufacturing have different standards, usually going from low 
purity (upstream) to highest purity (formulation). The EU GMP standards are categorized 
from A to D, A as the lowest amount of particles allowed in the m3 of air. Upstream 
process is often executed in cleanroom's categorized to D and C. Formulation and filling 
are often executed in cleanroom's categorized to B and A.  [Lane, 2016.] The size of the 
particles and operation modes (at rest or in operation), affects inside the standards to 
the allowed number of particles in the m3 of air. More particles in the air are allowed in 
the "in operation" mode, compared to "at rest" mode.  
5.1 Phases of Vaccine Development 
The development, testing and regulation of vaccines, evolved to the current system in 
the 1900’s. Development can take many years and if it succeeds, it could end up to a 
large-scale vaccination programme, for example EPI. Many of the vaccines fail at the 
beginning because they are unsuccessful to produce the desired immune response. Only 
a few of the possible vaccines make it to the licensing. [Stages of Vaccine Development, 
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2017.] Vaccine development is very expensive, but it is financially supported by many 
organizations. Phases of the development are shown in the Figure 5. 
Development of every vaccine starts with the exploratory stage. It consists of laboratory 
research to identify antigens that might be able to treat or prevent a disease. [Vaccine 
Development, Testing, and Regulation, 2018.] The found microorganisms are weakened 
or killed so that they cannot replicate and cause a disease anymore. The wanted part of 
the microorganism is used to manufacture a vaccine.  
In the EU, development of vaccines can be divided into two stages, pre-clinical and clin-
ical development [Stages in Vaccine Development, 2017]. Pre-clinical studies include 
laboratory and animal studies, once the wanted microorganism has been found and an-
tigens isolated. The purpose of pretesting is to assess safety, biological activity and for-
mulations. Animal studies can also help to see what kind of cellular responses is             
expected in humans. GMP standards are used when the cell line is constructed and cell 
banking is done. This stage can take already 6.5 years and cost about 350M dollars. 
[Lane, 2016.] 
In the stage of clinical development, the vaccine is tested in humans. The testing hap-
pens in four phases and can take many years. First three phases are the clinical trials. 
The stage of clinical development is based on strict ethical principles. Volunteers are well 
informed of the vaccine safety and efficacy. [Stages in Vaccine Development, 2017.]  
Phase 1 is done in small scale with 20 to 100 healthy volunteers. Its purpose is to deter-
minate safety and dosage [Lane, 2016.] In Europe, there is phase 1a and 1b. These are 
for testing vaccine for the diseases of poverty. Phase 1a is for European volunteers and 
phase 1b for volunteers in developing countries. [Stages in Vaccine Development, 2017.] 
Vaccines that are targeted to children, are first tested with adults. Volunteers in these 
studies are attentively monitored and the conditions are controlled. [Vaccine Develop-
ment, Testing, and Regulation, 2018.] 
Phase 2 is tested with a larger group of 100 to 500 patient volunteers. The purpose of 
this phase is to evaluate effectiveness of the vaccine versus clinical diseases and artifi-
cial infections. Immune response, alongside side-effects, are also evaluated and the 
method of the delivery is decided. [Stages in Vaccine Development, 2017.] In this phase 
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the trials are controlled and randomized. A group of people is also having a placebo 
vaccine in the tests. [Vaccine Development, Testing, and Regulation, 2018.] 
Phase 3 confirms effectiveness and monitors adverse events originating from long term 
use. This phase is tested with 1000-5000 patient volunteers to evaluate the effectiveness 
under natural disease conditions. [Lane, 2016.] The tests in this phase are randomized 
and the developed vaccine is tested against a placebo [Vaccine Development, Testing, 
and Regulation, 2018]. If the vaccine is safe and effective for a defined period, can the 
manufacturer apply for a license from the regulatory authorities. If the license is admitted, 
can the manufacturer start to market the vaccine for human use. [Stages in Vaccine 
Development, 2017.] 
In phase 4, the vaccine has been licensed and is available for the users. The vaccine is 
still being under surveillance and the aim is to detect adverse events. The effectiveness 
of the vaccine is monitored throughout its long-term use. [Stages in Vaccine Develop-
ment, 2017.] The vaccine development in US is approximately the same as in Europe, 
but different agencies are responsible for the surveillance and evaluating.  
 
Figure 5. Phases of Vaccine Development. 
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5.2 Production of the Vaccine Agent 
Process for manufacturing a biological preparation consists of upstream and down-
stream processes. There are different techniques and ways to produce a vaccine agent, 
but all the ways are based on upstream and downstream processes. These different 
techniques and ways are discussed in sections 5.2.2 and 5.2.3.  
Upstream includes the entire process from early cell isolation and cultivation, to cell 
banking, to the culture expansion of the cells fermentation process and the final harvest. 
Basically, the first step is the cell bank storage. The wanted cell line is taken from a 
working cell bank. Then comes the inoculum, which involves thawing of cells, use of a 
shake flask of 100 to 500 milliliters and a bioreactor of 3 to 20,000 litters. The cell culture 
is scaled up. Then comes the primary recovery, cell and debris removal. This involves 
centrifugation, depth membrane filtration and harvest. [Lane, 2016.] Section 5.2.1           
introduces a bioreactor more closely. 
5.2.1 Bioreactor 
Most bioreactors used in the vaccine production are stainless steel stirred-tank bioreac-
tors (STB). Bioreactor is part of the upstream process and is used for the growing of 
the microorganisms. It provides an environment, sterile conditions and agitation. Figure 
6 shows what STB consist of. Mixing is achieved by using the agitators and gas      
bubbles from the sparger. This type of bioreactor is typically used for microbial and 
mammalian cells. [Lane, 2016.] 
20 
 
 
Figure 6. Stirred-Tank Bioreactor [Lane, 2016]. 
5.2.2 Egg and Cell Culture-Based Manufacturing of Influenza Vaccine 
When producing influenza vaccine, egg and cell culture-based manufacturing methods 
are used, to create millions of vaccine doses. Every few years there is different kind of 
seasonal influenza virus infecting people and new vaccine must be made. Influenza       
effects globally so the manufacturing scale is huge.  
The WHO officials are working together with national health agencies to identify the virus 
strains that might cause the next influenza pandemic. The production of a new seasonal 
influenza vaccine is based on the surveillance that the WHO and the health agencies do. 
Production of a seasonal influenza vaccine is difficult because the WHO announces the 
seasonal strains on February, which gives manufacturers six months to develop a vac-
cine for the people of Northern Hemisphere and create a supply. Same applies for the 
Southern Hemisphere with an offset. This six month period includes the announcement 
of seed strains, monovalent vaccine production, approvals, vaccine formulation and the 
clinical trials. Virus growth and fulfilling the regulatory aspects are the most crucial parts 
for success on the six month period. [Milián & Kamen, 2015.] 
The egg-based manufacturing system is the most used method for production of an in-
fluenza vaccine. The method was developed in the 1940’s, almost 80 years ago. It uses 
embryonated hens’ eggs to replicate the virus. Advantages of this method are safety and 
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effectiveness that are well established. It has limitation as it needs constant supply of 
eggs. One or two eggs yield one vaccine dose. When the influenza pandemic outbreaks, 
the production of the vaccine might be problematic. Another disadvantage in the use of 
eggs is that it might leave some egg components that might cause an allergic reaction. 
Because the demand is increasing as the world population grows, scientist have intro-
duced new ways to mass produce influenza vaccines faster and safer. [Milián & Kamen, 
2015.] 
Cell culture-based manufacturing is one of the new ways to produce an influenza vaccine 
effectively. It uses mammalian cells to culture the influenza virus for vaccine production.  
Unlike in the egg-based manufacturing, this way can respond to market needs quickly. 
The production has also better process control, higher safety level and shorter production 
cycle. So higher quantities are made in a shorter period of time and pathogenic viruses 
can be produced safely. It also reduces the possibility of mutation of the virus culture in 
the manufacturing process. Problems for cell-based manufacturing are that the costs are 
relatively high and the cells should be free from another virus. The volumetric virus yields 
are lower than in the egg-based process. Since it is a new production method, it does 
not have long term safety data. [Milián & Kamen, 2015; Health Sciences Authority, 2014.] 
At the moment egg-based production is mainly used for civilian vaccines, like influenza 
vaccine and bacterial fermentation based vaccines. These products are made with old 
technologies and processing strategies. For these “old products” the manufacturing tech-
nology is not changing any time soon because of the work amount it would require. Reg-
ulatory process and obtaining the new licenses for the new processes would be too dif-
ficult and expensive to arrange. The manufactured products would also need a proof that 
the new technology can manufacture everything as effectively and safely as the old pro-
cess. Fortunately, new technologies can be used for new products. Cell culture methods 
can be used for virus particle-based vaccines. [Smart, 2013.] 
5.2.3 Batch Processing vs. Continuous Processing 
Batch processing is the old way of producing pharmaceuticals compared to continuous 
process. The traditional batch processing is showed in Figure 7 on the left side of the 
Figure. The process has at least six steps and six pieces of equipment before it is com-
pleted. The production stops every time when the equipment is changed. Components 
of the drug are added on through the process and new batch cannot start before the 
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previous one is completed. Advantages of using a batch processing are that the setting 
up is little bit less expensive and the process is easily modified. Some products can be 
only made with batch processing. [Batch vs. Continuous Pharmaceutical Manufacturing, 
2017.] 
In the continuous process, the product is done continuously, which means that there is 
no need to interrupt the process. The right side of the Figure 7 shows the continuous 
process. All the base ingredients are added at the beginning of the process. Advantage 
of using continuous processing is that it can speed up the process significantly compared 
to batch processing. It can also be more environment friendly option. Since the process 
is continuous and fewer people are involved in the process, the risk of human error is 
reduced. [Batch vs. Continuous Pharmaceutical Manufacturing, 2017.] 
 
Figure 7. Batch Process vs. Continuous Process [Massey, 2016]. 
Batch processing has been used for a long time by biopharmaceuticals when manufac-
turing vaccines. Continuous processing has been mainly used, for example, in the en-
ergy generation industries and in the food processing. The use of continuous process, 
when manufacturing vaccines, has been rising as a new way. Massachusetts Institute of 
Technology (MIT) and Novartis have perfected a continuous process for manufacturing 
a pharmaceutical product. [Challenges in the Development of Continuous Processes for 
Vaccines, 2017.] 
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It is challenging to develop continuous process for a vaccine because the production has 
many phases. The process involves upstream and downstream processes, which in-
clude harvest, immunogen separation and purification, multiple filtrations and chroma-
tography. It is expensive to maintain continuous substrate supply and sterilization. Sub-
unit vaccines require higher purity, compared to live-attenuated vaccines, because of the 
different dose levels. Downstream processing is the most challenging part of continuous 
process because it is so complex. When manufacturing a new vaccine, cost analysis is 
done and evaluation must be made whether the continuous process is better compared 
to the traditional manufacturing methods. If the continuous process is successful, it could 
decrease the costs and production time. Also, it would lessen the quality control valida-
tion because it is safer from contaminants. Continuous process development might be 
the new modern way of manufacturing vaccines. [Challenges in the Development of Con-
tinuous Processes for Vaccines, 2017.] 
5.3 Purification Methods of Downstream Processes 
Downstream involves separation of the cells from the media, isolation of the product, 
purifying, polishing and packaging of the product. In short, it is where the capturing of 
the desired protein happens. Harvesting happens between upstream and downstream 
processes. There the particulate matter is removed, for example cell debris. Capturing 
is the first purification step aiming at a volume reduction and partial purification of the 
product. After that comes few more purification steps to remove the contaminating so-
lutes. Polishing is the last purification step removing minor impurities, for example dena-
tured protein and aggregates. The whole downstream process includes ion exchange, 
affinity and HPLC chromatography and micro / ultra-filtration. Chromatographic tech-
niques are used in the purification. Filtration is used for the reduction of the volume and 
for removing impurities. Every step is done in cleanroom conditions. Downstream pro-
cess uses the purest water called Water for Injection (WFI). [Lane, 2016.] 
Making of toxoid vaccine describes well the upstream and downstream processes. (Up-
stream changes to downstream when the harvesting starts.) Toxins are produced by 
bacterial fermentation. Media preparation and the scale-up happens with fermentation 
process that takes about 42 hours. Harvest is done with centrifugation or microfiltration, 
using often a tangential-flow filtration. Particulate matter is removed by using 0.45 µm or 
0.22 µm membrane filters. Toxoidation is done with formalin that weakens the toxin. This 
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operation can take up to 42 days and is intensively monitored with sterility and pH testing. 
The resulting toxoid is concentrated with ultra- or diafiltration and then ammonium sulfate 
is added for precipitation. After that follows more concentrations steps and formulation 
using ultra- or diafiltration, before the final filtration for the filling. [Adams et al. 2011.] 
In the Figure 8 simplified upstream and downstream processes of influenza vaccine pro-
duction are shown. Upstream process includes the selection of the strains used in the 
production of vaccine and the growing of the selected microorganisms in a bioreactor. 
Harvesting and purification of the microorganisms happens between the upstream and 
downstream processes. Downstream process includes inactivation and splitting of the 
organism, formulation, quality control and packaging the vaccine. 
                  
Figure 8. Upstream and Downstream Processes of Influenza Vaccine Production. 
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5.3.1 Equipment Used in Downstream Processes 
In this section, examples of equipment used in the downstream process are introduced 
more closely. The examples picked for the thesis are affinity chromatography and tan-
gential flow filtration. 
Affinity chromatography is used in the downstream process for the purification of vaccine. 
Affinity chromatography is a separation method between immobilized ligand and its bind-
ing partner, for example antibody and antigen. To elute the target molecule from the 
affinity medium, the interaction can be reversed, either specifically using a competitive 
ligand or non-specifically, by changing the pH, ionic strength or polarity. [Lane, 2016.] 
Figure 9 shows the basic principle of affinity chromatography. First, the mixture of pro-
teins is poured to the column, as can be seen in the loading phase. In the separation 
phase, the target analyte binds with the immobilized receptor. Then, the wash is added 
to the column and the discard is flown through the column with the unwanted proteins. 
An elution buffer is added to the column and the target analyte flows through it. The 
target analyte is then purified from the other unwanted proteins and collected.   
 
Figure 9. Principle of Affinity Chromatography [Creative Biostructure, 2018]. 
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Tangential flow filtration (TFF) is filtration method used in downstream process of man-
ufacturing for example influenza vaccines. TFF is usually used for the concentration of 
the solution. It removes the fluid from a solution while retaining the solute molecules. 
Halving the solution volume can double the concentration. TFF is a rapid and efficient 
method for separation and purification of biomolecules. The product flow is directed tan-
gentially along the surface of a membrane, with most of the solution circulated back to 
the feed tank. Many processes in biopharma industry use this filtration method. It’s easy 
to set up and operate. It can also be scaled-up or scaled-down. TFF is economical be-
cause it can be cleaned and the cassettes can be reused as well as other parts of the 
device.  [Lane, 2016.] 
In Figure 10 a simple TFF device is shown. Pump moves the sample from sample res-
ervoir to the filter. The feed stream passes horizontally over the membrane. Ultrafiltration 
membranes filtrate the smallest particles and the retentate goes through the valve back 
to the sample reservoir. This continues until the wanted concentration is achieved. 
        
Figure 10. Simple Tangential Flow Filtration Device [Lane, 2016]. 
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5.4 Regulation of Vaccines 
The pharmaceutical industry is one of the most regulated industry known. Governments 
in all world regions have established regulatory agencies to ensure that every aspect of 
pharmaceutical activity is tightly controlled. The WHO does the recommendations for 
biological products that are used internationally. Many countries follow the WHO stand-
ards. [Lane, 2016.] 
National Regulatory Authorities (NRAs) are agencies which ensure that the pharmaceu-
ticals and biological products that goes to the market, meets the international expecta-
tions of quality and safety. All countries that produce vaccines, must follow six critical 
control functions. These functions are a published set of requirements for licensing, sur-
veillance of vaccine field performance, system of lot release, use of laboratory when 
needed, regular inspections for GMP and evaluation of clinical performance. [National 
Regulatory Authorities, 2018.] 
In the US there has been vaccine regulation for more than 100-years. The American 
regulatory authority is the Food and Drug Administration (FDA). FDA’s mission is to pro-
tect human health. Inside the FDA there is Centre for Biologics Evaluation and Research 
(CBER), which is responsible for Biologics, for example vaccines. FDA’s responsibilities 
include to decide if clinical trials can be allowed to begin, to protect rights of the volun-
teers participating in the clinical trials, to allow license for marketing and oversee the 
manufacturing process. [Lane, 2016.] 
European regulations have similar philosophy for the regulation but differ in the imple-
mentation of the legislation. Every European country has a national regulatory authority 
appointed by the government. European Medicines Agency (EMA) was established in 
the 1995 in attempt to streamline drug approval for all European countries. It supervises 
regulation of vaccines and other drugs. Japan is also a major leader in the pharmaceu-
tical markets. The ministry of health and welfare in Japan has overall responsibility to 
implement Japanese pharmaceutical law. [Lane, 2016.] 
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5.5 Single-use Technology 
For a long time, biopharmaceutical industries have used large stainless-steel bioreactors 
for the scale-up phase of production. Single-use technology is starting to compete 
against the old equipment. Advantages of this technology are that it reduces set-up time 
and cleaning, it eliminates possibility of cross-contamination, it is easy to use and the 
technology can be ordered as needed, so it won’t need a storage space. Downsides are 
that they can only be used once, they create waste and are limited in size. Usual single-
use technology products are single-use bags (small bioreactors), mixers and filters. 
[Lane, 2016.]  
At the moment the maximum size of single-use bag is 2000 liters. The sizes of single-
use bags are suitable for vaccine production because vaccine doses are small (meas-
ured in micrograms) and 200-2000 liters is enough for making a batch. Single-use tech-
nology is mainly used for new vaccines because of the regulation and licensing pro-
cesses. It would be expensive and slow to chance the production equipment of the old 
products.  
One example of single-use technology is WAVE bioreactor system. It consists of a pres-
terile disposable chamber that has cell culture medium inside. It is placed on top of a 
special rocking platform. Rocking creates waves that provides the mixing and oxygen 
transfer. WAVE bioreactor has 0.2 µm air filters, which allow gas to flow into and out of 
the bag. It also has sensors (e.g. pH), ports, tubes, connectors and clamps. Figure 11 is 
an example of a WAVE bioreactor system.  
                                                                                   
Figure 11. WAVE bioreactor system [Lane, 2016]. 
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 Future of Vaccines 
The future of vaccines presents continues challenges for creating effective vaccine, for 
example for HIV virus and against parasitic diseases, like malaria.  Production has to 
have lower costs, better delivery, and environmental endurance. Already existing vac-
cines are also developed further to be even more effective. 
If researchers would find a vaccine for HIV virus, it could be possible that the cost would 
be so high that the poorer countries could not afford it. Developing countries usually need 
it the most. Also, the delivery might be very difficult to some areas. Vaccine materials for 
the tolerance of different temperatures and delivery methods should be improved, so that 
the vaccine could remain viable through the transportation and storing. Vaccination pro-
grammes should also be improved in a way that they would be available for everyone, 
especially to the places where vaccination is poor or non-existing at the moment. [The 
Future of Immunization, 2018.] 
New delivery methods of vaccines are also researched. MIT has been investigating a 
new approach for the giving of booster shot. They are developing a new technique where 
multiple vaccine shots could be given as one shot by capsuling the shots within tiny 
biodegradable polymers. Depending on the polymer, they would break down at different 
times and release the contents to the body. It would be valuable invention for treatments 
of diabetes, allergies and other situations where multiple shots are needed. According to 
Ana Jaklenec from MIT, this invention would be important for developing countries where 
mothers rarely bring their children to get booster shots. [Davis Nicola, 2017.] 
In the process tiny silicone molds are made. Biodegradable polymers are then added to 
the molds, to create box-like shape, around 400 µm across. Then, the molds are filled 
with the vaccine and dried. Biodegradable polymers have already been approved to hu-
man use and animal tests with the capsulated vaccines have showed to be successful. 
[Davis Nicola, 2017.] 
The production of vaccines has already showed new ways to enhance the manufacturing 
and new procedures. New ideas are constantly invented to help to improve the immune 
system against various diseases. Manufacturing is evolving with new techniques, for ex-
ample using single-use technologies. Molecular biology has evolved a lot in few decades 
and is now applied to the research and production with DNA technology. 
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6.1 Recombinant Vaccines 
Recombinant vaccines are the new kind of vaccines developed by a new recombinant 
DNA technology (DNA = Deoxyribonucleic Acid). It is a technique where genes from one 
organism are isolated, purified and then reproduced in another organism and it is often 
performed through ligation [Cruse & Lewis, 2009:614.] Vaccines manufactured by using 
a recombinant DNA technology are safe and production costs are lower compared to 
traditional vaccines. Vaccines made by this technology can be divided to DNA vaccines 
and recombinant (protein subunit) vaccines. These vaccine types are discussed more in 
sections 6.2 and 6.3. 
6.1.1 Expression systems 
Expression systems are important parts of recombinant DNA technology. Expression 
system is a combination of DNA to be cloned, expression vector (often a plasmid) and 
host cell. Expression system is manipulated to produce high levels of desired protein. 
[Lane, 2016.] Bacteria, yeast, insect and mammalian cells are used as protein                  
expression systems. The features of target protein effects, which system is used. The 
features are sequencing, structure, activity, function, folding and post translational     
modification. Bacterium and yeast are the least expensive options, but the yield (mg/L) 
is not that good compared to mammalian cells. [Choosing a Protein Expression System, 
2018.]  
6.1.2 Adjuvants 
Adjuvants that enhance the immunity in vaccines are main reason for the recombinant 
vaccines to be successful. These vaccines would not give a good protection against  
diseases if they would not include any adjuvants. The use of aluminium salt as adjuvant 
made the success of vaccines against hepatitis B virus and human papillomavirus.         
Investigation of new adjuvants has showed to be extremely important. [Nascimento & 
Leite, 2012.] 
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6.1.3 Prime-Boost 
Some vaccines need a booster shot to maintain the protection against diseases. This 
kind of shot is called homologous prime-boost because it uses same formulation. Now 
scientists are testing a heterologous prime-boost immunization, where the antigens are 
the same but formulated in different ways. They can be either purified antigens or re-
combinant proteins with appropriate adjuvants. These adjuvants can be DNA vaccines 
or live recombinant viral or bacterial vector vaccines. This method appears to be able to 
induce a better immune response. It is more efficient because it combines both humoral 
and cell-mediated immunity. It has showed potential in the animal testing phase of HIV 
vaccine development. [Nascimento & Leite, 2012.] 
6.2 DNA Vaccines 
For over a hundred of years there have been two approaches to create immunity by 
vaccination: attenuation or inactivation of pathogens. Researchers have investigated 
new ways as the knowledge of molecular biology and technology has improved. As a 
result, DNA vaccines have been invented.  
DNA vaccines are immunizing preparations, which include a gene that encodes the      
antigens, instead of having the antigens ready in the vaccine. Thus, it includes the       
“recipe” for making the wanted antigens. [Donnelly et al., 2005.] Gene that is responsible 
for encoding the antigen is inserted into a bacterial plasmid. This plasmid is then injected 
to the muscle cells of the host. For manufacturing and expressing the antigen, the gene 
uses the nuclear machinery of the host cell. DNA vaccines are able to induce both hu-
moral and cell-mediated immune responses. [Cruse & Lewis, 2009:233.]  
Plasmid in DNA vaccine contains one origin of the replication, E. coli, for the amplification 
of the plasmid. A strong promoter, multiple cloning sites and antibiotic selection marker 
are also included to the plasmid. The bacterium is isolated and purified for the vaccine. 
The idea of the DNA vaccine is based on what is occurring during a viral infection. Anti-
gen is expressed directly by the host cells. As a result, it is possible for antigens to be 
processed as proteins that are synthesized in the cytoplasm. DNA vaccines have no risk 
of infection and strong and lasting immunity might be possible to achieve. [Nascimento 
& Leite, 2012.] DNA vaccine for HIV virus has been on development for 20 years and 
has entered the human trials phase. Unfortunately, DNA vaccine for HIV virus has 
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showed low immunogenicity in humans. It is extremely important to discover a suitable 
adjuvant to enhance the immunity. 
The first DNA vaccines in the market will use a plasmid from bacterial cells. In the future, 
it might be possible to use RNA (Ribonucleic Acid) or other complexes of nucleic acid 
molecules. The development is evolving rapidly and new guidelines are needed for reg-
ulation. Control should be flexible for the modifying as the experience is gained in the 
production and use. [DNA Vaccines, 2018.] 
6.3 Recombinant Protein Subunit Vaccines 
Recombinant protein is a form of protein that has been manipulated. The gene has been 
isolated and cloned into an expression vector. A vector is a segment of DNA that can 
clone a foreign DNA fragment and autonomically reproduce in the host cell [Cruse & 
Lewis, 2009:739.] Recombinant proteins are often made for therapeutic use. The genes 
are usually coming from humans but they are expressed in other organisms. [Clark & 
Pazdernik, 2016.] 
Recombinant protein subunit vaccine is a subunit vaccine that contains only a small 
part of the germ. These are often synthetic peptides that work as the protein compo-
nents by inducing the immune response. Also, antigens that are expressed in a        
heterologous system, made by recombinant protein expression technologies, can be 
used. Vaccines that are made nowadays often use this technology to purify recombi-
nant proteins or antigen subunits. Currently there is Hepatitis B virus vaccine made   
using this technology and it is in the market for humans. [Recombinant Vaccine, 2018.] 
Figure 12 shows the production steps of Hepatitis B virus vaccine. Plasmid DNA is taken 
from bacterium and cut with restriction enzymes. The gene that produces Hepatitis B 
antigen is isolated from Hepatitis B virus and combined with the cut plasmid DNA. Re-
combinant DNA is made and introduced to a yeast cell. The recombinant yeast cell is 
moved to a fermentation tank to multiply. Hepatitis B antigen is produced in the fermen-
tation tank. After the multiplying, the Hepatitis B antigen is extracted and purified. Finally 
the hepatitis B vaccine is formulated to its final form. 
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 Figure 12. Production of Hepatitis B Vaccine by DNA technology [GenScript, 2018]. 
6.4 Mutation of Viruses 
Mutations of viruses is a continuous problem for all RNA virus based vaccines. The evo-
lution of a strain is hard to foretell. In RNA viruses the genetic material is encoded by 
RNA, instead of DNA. RNA is not as stable molecule as DNA and result from this is that 
if there are mistakes in the copying of RNA, there is no build-in proofreading that would 
repair the mistake. Virus mutations in RNA happen frequently. Therefore, it is very diffi-
cult to create one vaccine for influenza viruses or a working vaccine for HIV virus.  [Vi-
ruses and Evolution, 2018.] 
 Conclusions 
Vaccine manufacturing is a long and expensive process. Vaccines have proven to have 
important influence in the human health. The field of vaccines is evolving rapidly and 
new findings are constantly made. The future of vaccines depends on the successful 
medical research and new vaccine technologies for the development.  
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With good immunization programmes, eradication of vaccine preventable diseases is 
possible, but a working immunization programme with efficient vaccines is not enough. 
For a disease to be eradicated, the programme needs to include the whole world, it needs 
the vaccines to be given to everyone, everywhere, even to the areas that are hard to 
reach. Eradication is already close for measles and polio virus.  
 
Vaccines need to be affordable to everyone, so the costs of vaccine development and 
manufacturing must be low. New ways are searched to get the costs as low as possible. 
Also new ingredients are researched to enhance the stability and endurance of the       
vaccine. 
 
Knowledge about health and vaccination should be taught to everyone. Constantly grow-
ing population is a risk because diseases will spread more easily in the very crowded 
places. Basic hygiene, for example, hand washing, will already decrease possibility to 
the disease to spread. Childhood vaccination will provide good and lasting immunity to 
children and still effect in the adulthood. It will also help to prevent diseases from     
spreading in a population, in a long-term.     
                              
Adverse events of immunization are under surveillance and the information gathered, 
will help with the development of vaccines. Reporting adverse events is extremely          
important because there is not often any long-term information about possible undesired 
reactions that the vaccines might cause. Even though the development process is long 
and well established and regulated, it is possible that some of the adverse events will 
not appear in the trial phases. This can cause problems after the vaccine is provided to 
larger groups of people.  
 
In conclusion vaccines are important preparations with proven health benefits. The de-
velopment is difficult with its many time-consuming phases, high costs and regulations. 
Research and development of vaccines are financially supported by governments, foun-
dations and by private people. Vaccines have saved millions of lives in the past 200 
years and will continue to do so, and maybe eventually have even the ability to cure.  
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